Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

National Institute on Drug Abuse (NIDA)1 site in 1 country16 target enrollmentSeptember 2001

ConditionsAmphetamine-Related Disorders

DrugsSelegiline

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Amphetamine-Related Disorders
Sponsor: National Institute on Drug Abuse (NIDA)
Enrollment: 16
Locations: 1
Primary Endpoint: pharmacokinetic assessment
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Detailed Description

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg \& 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Registry

clinicaltrials.gov

Start Date

September 2001

End Date

October 2002

Last Updated

9 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

National Institute on Drug Abuse (NIDA)

Eligibility Criteria

Inclusion Criteria

•Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
•Be able to verbalize understanding of consent form; provide written informed consent